Shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX – Get Free Report) traded down 7.3% during trading on Thursday . The company traded as low as $15.39 and last traded at $15.39. 21,206 shares changed hands during trading, a decline of 95% from the average session volume of 400,743 shares. The stock had previously closed at $16.61.
Wall Street Analysts Forecast Growth
A number of research analysts recently weighed in on the stock. Leerink Partnrs reiterated an “outperform” rating on shares of Kyverna Therapeutics in a research note on Monday, March 4th. JPMorgan Chase & Co. initiated coverage on Kyverna Therapeutics in a report on Monday, March 4th. They set an “overweight” rating and a $39.00 price objective on the stock. Wells Fargo & Company initiated coverage on Kyverna Therapeutics in a research note on Monday, March 4th. They issued an “overweight” rating and a $44.00 target price for the company. SVB Leerink assumed coverage on Kyverna Therapeutics in a research report on Monday, March 4th. They set an “outperform” rating and a $48.00 price target on the stock. Finally, Morgan Stanley began coverage on shares of Kyverna Therapeutics in a report on Monday, March 4th. They issued an “overweight” rating and a $40.00 price target on the stock. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Kyverna Therapeutics currently has an average rating of “Buy” and a consensus target price of $42.75.
View Our Latest Report on KYTX
Kyverna Therapeutics Price Performance
Insider Buying and Selling at Kyverna Therapeutics
In other Kyverna Therapeutics news, major shareholder Northpond Ventures Iii Gp, Llc acquired 450,000 shares of the business’s stock in a transaction dated Monday, February 12th. The stock was bought at an average price of $22.00 per share, with a total value of $9,900,000.00. Following the completion of the acquisition, the insider now owns 450,000 shares of the company’s stock, valued at $9,900,000. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Kyverna Therapeutics Company Profile
Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.
Featured Articles
- Five stocks we like better than Kyverna Therapeutics
- How to invest in marijuana stocks in 7 steps
- Meta Stock: 3 Reasons This Stumble Is a Golden Buying Opportunity
- 3 Warren Buffett Stocks to Buy Now
- 3 Staples Stocks to Cushion Lower Consumer Sentiment
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Zillow’s Earnings Dip: An Opportunity for Visionaries
Receive News & Ratings for Kyverna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kyverna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.